Key Compliance Changes for Pharma Companies
On 28 January 2025, the Italian Council of Ministers approved a new legislative decree aligning Italy with the EU Falsified Medicines Directive (FMD). This long-awaited update introduces a two-year stabilization period, giving pharmaceutical manufacturers time to transition from the current national traceability system to the EU-compliant serialization model.
For companies operating in Italy, this means critical adjustments in compliance, supply chain processes, and product verification systems.
During this phase, pharmaceutical manufacturers can choose between continuing with Italy’s existing system (Bollino Farmaceutico) or switching to EU FMD serialization (unique identifier and anti-tampering label).
After 8 February 2027, full compliance with the EU serialization model will be mandatory.
For Marketing Authorization Holders (MAHs), CMOs, and parallel importers, this is a critical time to prepare. Companies must:
We provide Serialization consulting, implementation & integration services to help our clients with managing the end-to-end serialization projects and preparing them for the existing and upcoming regulations across the globe.
We are well versed with the compliance regulations for various markets and can help you with implementing the Nigerian pharmaceutical serialization requirements as and when the regulations evolve.
Our team of experts strategize and plan end-to-end solutions using a combination of years of knowledge in product serialization and pharmaceutical supply chains.
CONCLUSION: In today’s evolving global landscape, traceability is more than a regulatory requirement — it’s a strategic imperative. Our advanced solutions help your organization achieve seamless compliance, end-to-end transparency, and the highest standards of pharmaceutical safety.
Driven by compliance. Defined by excellence.
Speak with a VariTec Compliance Expert.